Published in Oncologist on April 08, 2011
Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. J Clin Oncol (2013) 1.46
Oxaliplatin-induced neuropathy in colorectal cancer. J Oncol (2011) 1.07
Oxaliplatin-induced peripheral neuropathy's effects on health-related quality of life of colorectal cancer survivors. Support Care Cancer (2013) 1.02
Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer (2012) 0.98
A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. Pharmacogenomics J (2012) 0.95
Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: is it a trade-off between drug efficacy and toxicity? Oncologist (2011) 0.92
A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer (2014) 0.90
Management options for established chemotherapy-induced peripheral neuropathy. Support Care Cancer (2014) 0.84
A polyamine-deficient diet prevents oxaliplatin-induced acute cold and mechanical hypersensitivity in rats. PLoS One (2013) 0.83
Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients. World J Gastroenterol (2013) 0.80
Nerve excitability assessment in chemotherapy-induced neurotoxicity. J Vis Exp (2012) 0.80
Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic review. Crit Rev Oncol Hematol (2015) 0.80
Complex impairment of IA muscle proprioceptors following traumatic or neurotoxic injury. J Anat (2015) 0.80
The influence of chemotherapy-induced neurotoxicity on psychological distress and sleep disturbance in cancer patients. Curr Oncol (2014) 0.79
Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment. Support Care Cancer (2016) 0.77
Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer. Oncology (2016) 0.77
A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer. Support Care Cancer (2014) 0.76
A novel path to chronic proprioceptive disability with oxaliplatin: Distortion of sensory encoding. Neurobiol Dis (2016) 0.76
Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review. Front Pharmacol (2017) 0.75
Burning pain: axonal dysfunction in erythromelalgia. Pain (2017) 0.75
Peripheral nerve axonal excitability studies: expanding the neurophysiologist's armamentarium. Cerebellum Ataxias (2015) 0.75
Lifestyle-Related Factors in the Self-Management of Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer: A Systematic Review. Evid Based Complement Alternat Med (2017) 0.75
Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet-NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial. BMJ Open (2015) 0.75
Disease burden and pain in obese cancer patients with chemotherapy-induced peripheral neuropathy. Support Care Cancer (2017) 0.75
The effect of n-3 polyunsaturated fatty acids on incidence and severity of oxaliplatin induced peripheral neuropathy: a randomized controlled trial. Biomark Res (2016) 0.75
Impact of oxaliplatin-induced neuropathy in patients with colorectal cancer: a prospective evaluation at a single institution. Curr Oncol (2016) 0.75
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med (2004) 18.93
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol (2000) 16.83
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol (2003) 11.94
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol (2009) 9.24
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol (2004) 3.10
Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve (1998) 2.61
Total neuropathy score: validation and reliability study. Neurology (1999) 2.15
Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol (1998) 2.11
Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol (2002) 2.11
The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer (2005) 2.09
The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst (2007) 2.01
Excitability of human axons. Clin Neurophysiol (2001) 1.96
Oxaliplatin-safety profile: neurotoxicity. Semin Oncol (2003) 1.94
Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve (2004) 1.91
Multiple measures of axonal excitability: a new approach in clinical testing. Muscle Nerve (2000) 1.88
Sensory conduction of the sural nerve in polyneuropathy. J Neurol Neurosurg Psychiatry (1974) 1.83
Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol (2007) 1.77
Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer (1999) 1.72
Persistent neuropathy after treatment with cisplatin and oxaliplatin. Acta Oncol (2009) 1.61
Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain (2009) 1.50
The Rochester Diabetic Neuropathy Study: reassessment of tests and criteria for diagnosis and staged severity. Neurology (1992) 1.38
Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve (2005) 1.37
Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol (2009) 1.37
NCCN task force report: management of neuropathy in cancer. J Natl Compr Canc Netw (2009) 1.35
Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology (2003) 1.28
Axonal ion channels from bench to bedside: a translational neuroscience perspective. Prog Neurobiol (2009) 1.27
Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol (1998) 1.21
Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst (2006) 1.15
Thalidomide-induced neuropathy. Neurology (2002) 1.11
Clinical evaluation of excitability measures in sensory nerve. Muscle Nerve (2001) 1.03
Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol (2006) 1.01
Why and how to study the fate of cancer survivors: observations from the clinic and the research laboratory. Eur J Cancer (2003) 1.01
Oxaliplatin and axonal Na+ channel function in vivo. Clin Cancer Res (2006) 1.00
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2007) 25.52
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med (2013) 16.24
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA (2010) 6.65
Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol (2012) 4.91
Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology (2008) 4.50
Balancing selection at the prion protein gene consistent with prehistoric kurulike epidemics. Science (2003) 3.59
HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet (2009) 3.03
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
Agreement between self-reported breast cancer treatment and medical records in a population-based Breast Cancer Family Registry. J Clin Oncol (2005) 2.70
Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res (2008) 2.66
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol (2014) 2.64
Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol (2013) 2.52
A systematic review of the effect of waiting for treatment for chronic pain. Pain (2007) 2.52
Guillain-Barré syndrome: an update. J Clin Neurosci (2009) 2.46
Biological variation of glycohemoglobin. Clin Chem (2002) 2.38
Differential microRNA regulation of HLA-C expression and its association with HIV control. Nature (2011) 2.36
Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol (2009) 2.20
Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev (2005) 2.14
Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency. Int J Cancer (2008) 2.09
Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol (2011) 2.08
Botulinum toxin modulates cortical maladaptation in post-stroke spasticity. Muscle Nerve (2013) 2.00
Postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: patterns of failure. Oral Oncol (2012) 1.98
Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain (2008) 1.94
Cancer patient preferences for communication of prognosis in the metastatic setting. J Clin Oncol (2004) 1.88
Role of pancreatic stellate cells in pancreatic cancer metastasis. Am J Pathol (2010) 1.87
Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. J Clin Oncol (2011) 1.78
What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? Lancet Oncol (2005) 1.77
Pancreatic stellate cells and pancreatic cancer cells: an unholy alliance. Cancer Res (2008) 1.77
Isolated bulbar phenotype of amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2011) 1.75
Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncol (2007) 1.74
Immunohistochemistry for SDHB divides gastrointestinal stromal tumors (GISTs) into 2 distinct types. Am J Surg Pathol (2010) 1.73
Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol (2009) 1.70
Half of patients with obstructive sleep apnea have a higher NREM AHI than REM AHI. Sleep Med (2006) 1.66
Segmental facial anhidrosis and tonic pupils with preserved deep tendon reflexes: a novel autonomic neuropathy. J Neuroophthalmol (2005) 1.63
Clinical trials of palliative chemotherapy in platinum-resistant or -refractory ovarian cancer: time to think differently? J Clin Oncol (2013) 1.63
Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology (2011) 1.59
Cortical excitability distinguishes ALS from mimic disorders. Clin Neurophysiol (2011) 1.59
Solitary extramedullary plasmacytoma of the head and neck--long-term outcome analysis of 68 cases. Head Neck (2008) 1.56
Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Arch Neurol (2011) 1.55
Adjuvant chemotherapy for early colon cancer: what survival benefits make it worthwhile? Eur J Cancer (2010) 1.55
Cortical excitability testing distinguishes Kennedy's disease from amyotrophic lateral sclerosis. Clin Neurophysiol (2008) 1.54
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst (2013) 1.54
Split-hand index for the diagnosis of amyotrophic lateral sclerosis. Clin Neurophysiol (2012) 1.52
Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain (2009) 1.50
Primary pancreatic lymphoma--pancreatic tumours that are potentially curable without resection, a retrospective review of four cases. BMC Cancer (2006) 1.49
Changes in human sensory axonal excitability induced by an ischaemic insult. Clin Neurophysiol (2008) 1.49
Progressive axonal dysfunction and clinical impairment in amyotrophic lateral sclerosis. Clin Neurophysiol (2012) 1.49
Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain (2006) 1.47
Corticomotoneuronal function in asymptomatic SOD-1 mutation carriers. Clin Neurophysiol (2010) 1.47
Detection of water in the LCROSS ejecta plume. Science (2010) 1.44
Multiple origins of Ashkenazi Levites: Y chromosome evidence for both Near Eastern and European ancestries. Am J Hum Genet (2003) 1.44
FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. J Neurol Neurosurg Psychiatry (2009) 1.44
Riluzole: a glimmer of hope in the treatment of motor neurone disease. Med J Aust (2005) 1.42
Regional differences in ulnar nerve excitability may predispose to the development of entrapment neuropathy. Clin Neurophysiol (2010) 1.41
Response to letter to the editor with reference to article "Postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: patterns of failure". Oral Oncol (2013) 1.40
Scurvy and stroke - is there an association? Med J Aust (2010) 1.40
Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group. Leuk Lymphoma (2011) 1.39
Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve (2005) 1.37
Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol (2009) 1.37
STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review). Int J Oncol (2012) 1.36
Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin (2014) 1.36
Genomewide association study for determinants of HIV-1 acquisition and viral set point in HIV-1 serodiscordant couples with quantified virus exposure. PLoS One (2011) 1.35
Neurotoxic marine poisoning. Lancet Neurol (2005) 1.33
Remoteness of residence and survival from cancer in New South Wales. Med J Aust (2004) 1.33
Motor neuron dysfunction in frontotemporal dementia. Brain (2011) 1.31
Uremic neuropathy: clinical features and new pathophysiological insights. Muscle Nerve (2007) 1.30
Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy. J Clin Oncol (2011) 1.29
Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol (2013) 1.29
Axonal ion channels from bench to bedside: a translational neuroscience perspective. Prog Neurobiol (2009) 1.27
Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: case report. BMC Cancer (2004) 1.26
Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clin Cancer Res (2012) 1.25
Genomic microsatellites as evolutionary chronometers: a test in wild cats. Genome Res (2002) 1.25
Framing effects in younger and older adults. J Gerontol B Psychol Sci Soc Sci (2005) 1.22
Axonal excitability properties in amyotrophic lateral sclerosis. Clin Neurophysiol (2006) 1.22
Prognosis of premenopausal breast cancer and childbirth prior to diagnosis. J Clin Oncol (2004) 1.20
Pathophysiology of neurodegeneration in familial amyotrophic lateral sclerosis. Curr Mol Med (2009) 1.19
Does interneuronal dysfunction contribute to neurodegeneration in amyotrophic lateral sclerosis? Amyotroph Lateral Scler (2012) 1.18
Fatigue in multiple sclerosis: mechanisms and management. Clin Neurophysiol (2010) 1.18
Altered nerve excitability properties in established diabetic neuropathy. Brain (2005) 1.17
Assessment of cortical excitability using threshold tracking techniques. Muscle Nerve (2006) 1.17